https://www.cruk.cam.ac.uk/publications/diagnostic-assay-based-on-hsamir205-expression-distinguishes-squamous-from-nonsquamous-nonsmallcell-lung-carcinoma/
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous...
Authors: D Lebanony, H Benjamin, S Gilad, M Ezagouri, A Dov, K Ashkenazi, N Gefen, S Izraeli, G Rechavi, H Pass, D Nonaka, J Li, Y Spector, N Rosenfeld, A...
based on
https://pubmed.ncbi.nlm.nih.gov/23628816/
Analytical validation of a practical molecular assay prognostic of survival in nonsquamous...
A molecular assay prognostic of survival in resected nonsquamous non-small cell lung cancer designed to meet the need for improved risk stratification in...
of amolecular assayanalyticalvalidationpractical
https://pmc.ncbi.nlm.nih.gov/articles/PMC9168140/
Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of...
NSCLC is a solid tumor with a growing number of actionable biomarkers that may inform treatment. Current guidelines recommend a broad, panel-based approach be...
in the united states
https://pubmed.ncbi.nlm.nih.gov/30370125/
Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what...
Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?
small cell lung cancer
https://pubmed.ncbi.nlm.nih.gov/26412456/?dopt=Abstract
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than...
small cellnivolumabversusdocetaxeladvanced